NCT02884284

Brief Summary

In order to accelerate border crossing between basic research and clinical research in breast cancer, it is necessary to easily use clinical and biological data. That is the reason why it is very important to create a clinical, biological and pathologic beast cancer database, mainly prospective but also retrospective. All data are from patients treated in Toulouse Centre. The scientific community will easily have access to clinical and biological informations through a centralized, structured database , leading to optimize patients with breast cancer treatment.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
10,000

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Feb 2015

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2015

Completed
1.5 years until next milestone

First Submitted

Initial submission to the registry

July 28, 2016

Completed
1 month until next milestone

First Posted

Study publicly available on registry

August 31, 2016

Completed
8.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2025

Completed
11 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2025

Completed
Last Updated

August 31, 2016

Status Verified

August 1, 2016

Enrollment Period

9.9 years

First QC Date

July 28, 2016

Last Update Submit

August 25, 2016

Conditions

Breast Cancer

Keywords

breast cancerdatabase

Outcome Measures

Primary Outcomes (1)

  • Database of patients with breast cancer

    10 years

Interventions

clinical biological database collectionOTHER

Eligibility Criteria

Age18 Years+
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Female patient with breast cancer of any stage

You may qualify if:

  • Female patient
  • Histologically confirmed breast cancer of any stage
  • Affiliated to a social security system in france
  • Who signed the informed consent

You may not qualify if:

  • Any psychiatric or medical condition that would make the patient unable to give a signed informed consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Institut claudius regaud IUCT ONCOPOLE

Toulouse, 31059, France

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

blood samples and tumor samples of patients treated for breast cancer

MeSH Terms

Conditions

Breast Neoplasms

Condition Hierarchy (Ancestors)

Neoplasms by SiteNeoplasmsBreast DiseasesSkin DiseasesSkin and Connective Tissue Diseases

Study Officials

  • Florence DALENC, MD

    Institut claudius regaud Toulouse ONCOPOLE

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Florence DALENC, MD

CONTACT

5 31 15 51 22dalenc.florence@iuct-oncopole.fr

Study Design

Study Type
observational
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 28, 2016

First Posted

August 31, 2016

Study Start

February 1, 2015

Primary Completion

January 1, 2025

Study Completion

December 1, 2025

Last Updated

August 31, 2016

Record last verified: 2016-08

Data Sharing

IPD Sharing
Will not share

Locations

FR(1)